Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Participate in Upcoming August Investor Conferences

Wednesday, July 31, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, a gene editing company, announced its participation in upcoming investor conferences. The company is known for its proprietary ARCUS platform, which is focused on developing in vivo gene editing therapies. These therapies aim to achieve sophisticated gene edits such as elimination, insertion, and excision.
Price reaction · baseline $9.55 (2024-07-30 close) · hit pre-market · 2 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is participating in investor conferences.
  • The company is advancing gene editing therapies.
  • Utilization of the novel ARCUS platform is highlighted.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Jul. 31, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

Frequently Asked Questions

What is Precision BioSciences known for?

Precision BioSciences is known for its advanced gene editing technologies.

What platform does Precision BioSciences use?

The company utilizes its proprietary ARCUS platform for gene editing.

When will Precision BioSciences participate in investor conferences?

Precision BioSciences is set to participate in upcoming investor conferences in August.

What types of gene edits does ARCUS focus on?

ARCUS focuses on gene elimination, insertion, and excision.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform investor conferences
Last updated: Jul 31, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →